‘The Worldwide Vaccines Market Will Reach $20.8bn in 2015′ Says Visiongain Report

LONDON, October 11, 2011 -

www.visiongain.com/Report/695/Vaccine-Manufacturing-Technology-and-Services-World-Market-2011-2021

A new report by visiongain, a London-based business information provider, forecasts that the worldwide vaccines market will reach $20.8bn in 2015. That market generated $10.7bn in 2010, according to Vaccine Manufacturing Technology and Services: World Market 2011-2021, published in October 2011.

Markets and R&D pipelines for vaccines remain strong, with opportunities for vaccine manufacturing specialists. Pharmaceutical companies and contract manufacturing organisations (CMOs) will benefit. In 2011, leading manufacturers of vaccines include Sanofi, Merck & Co. and GSK. This new study forecasts potential revenues for vaccines at total world and submarket levels to 2021. It also shows revenue predictions for contract vaccine manufacturing. There are forecasts of vaccine volumes (by dose), including geographical production data.  

Dr Sharmarke Mohamed, healthcare industry analyst, says: “Vaccines are responsible for some of the greatest public health triumphs. Those achievements include the eradication of naturally-occurring smallpox. Historically, the vaccines market had a wide range of companies vying for market share. However, small-molecule therapies took centre stage at the expense of vaccines. Looking ahead, we expect greater competition in the vaccines market, with more companies making significant headway. Leading companies will react by diversifying their portfolios with new therapeutic vaccines and outsourcing more vaccine manufacturing. Also, universities and other research institutions will play a significant role in the discovery of therapeutic vaccines.”

Visiongain predicts that the vaccines industry and market will grow steadily to 2021. The future of vaccine manufacturing is promising, with potential benefits for pharma companies, contract manufacturers, patients and healthcare providers. This new report adds to visiongain’s wide range of analytical reports for healthcare and other industries.

To see sample pages please click on:

www.visiongain.com/Report/695/Vaccine-Manufacturing-Technology-and-Services-World-Market-2011-2021

Web: www.visiongain.com

Table of Contents
1. Executive Summary
1.1 Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction to Vaccines
2.1 Basics of Vaccines
2.2 Utility of Vaccines
2.3 Formulation of Vaccines
2.4 Types of Vaccines
2.4.1 Live, Attenuated Vaccines
2.4.2 Recombinant Live Vaccines
2.4.3 Inactivated Vaccines
2.4.4 Toxoid Vaccines
2.4.5 Subunit Vaccines
2.4.6 Conjugate Vaccines
2.4.7 Recombinant Subunit Vaccines
2.4.8 DNA Vaccines
2.4.9 Recombinant Vector Vaccines
2.5 Diseases Preventable with Vaccines
2.5.1 Chickenpox and Shingles
2.5.2 Cholera
2.5.3 Diphtheria
2.5.4 Haemophilus Influenza Type B (Hib) Diseases
2.5.5 Hepatitis A
2.5.6 Hepatitis B
2.5.7 Human Papillomavirus (HPV) - Cervical Cancer
2.5.8 Influenza
2.5.8.1 Seasonal Influenza
2.5.8.2 Pandemic Influenza
2.5.8.3 Influenza Vaccination
2.5.9 Japanese Encephalitis
2.5.10 Measles
2.5.11 Meningococcal Diseases (Neisseria Meningitidis)
2.5.12 Mumps
2.5.13 Pertussis
2.5.14 Polio
2.5.15 Rabies
2.5.16 Rotavirus Infections
2.5.17 Rubella
2.5.18 Streptococcus Pneumoniae Infections
2.5.19 Tetanus
2.5.20 Tuberculosis
2.6 Vaccine Manufacture within the Biopharmaceutical Industry
2.6.1 Introduction
2.6.2 GlaxoSmithKline
2.6.2.1 Havrix
2.6.2.2 Engerix-B
2.6.2.3 Twinrix/Ambirix
2.6.3 Merck & Co.
2.6.3.1 Gardasil
2.6.4 Novartis
2.6.4.1 Optaflu (Novartis)
2.6.4.2 Pre-Pandemic Vaccines (Novartis)
2.6.5 Sanofi Pasteur
2.6.5.1 Sanofi’s H5N1 Influenza Vaccine Programme
2.6.6 Wyeth (Pfizer)
2.6.6.1 Prevnar/Prevenar (Wyeth)

3. Summary of the Global Vaccine Manufacturing Market, 2011-2021
3.1 Overview of the Global Vaccine Manufacturing Market, 2011-2021
3.2 Novel Technologies for Vaccine Manufacturing
3.3 New Substrates for Vaccine Manufacturing
3.3.1 Shift from Egg-Based Manufacturing to Cell-Based Manufacturing Technology
3.3.2 Cell-Based Techniques Clearly Have Advantages
3.3.3 Mammalian Cell Lines
3.3.3.1 MCDK (Madin Darby Canine Kidney Cells)
3.3.3.2 Vero Cells
3.3.3.3 PerC6 Cells
3.3.4 Avian-Derived Cell Lines
3.3.4.1 EB66 Stem Cell Technology: Vivalis
3.3.5 Plant-Based Vaccines
3.3.5.1 Medicago’s Proficia VLP Vaccine Technology
3.3.6 Insect Egg-Based Production Systems
3.3.6.1 Novavax
3.3.6.2 Protein Sciences Corporation (PSC)
3.4 Next-Generation Expression Systems and Vectors: Increasing Production Yield
3.4.1 AdVac Technology: Crucell
3.4.2 AdCEV Vectors: AfriVax
3.4.3 Pfenex Expression Technology: Pfenex

4. The Global Vaccine Manufacturing Market, 2011-2021
4.1 The Global Vaccines Market, 2010
4.1.1 Vaccine Types
4.1.2 Leading Vaccine Types by Revenue
4.1.3 Leading Vaccine Manufacturers
4.2 Global Vaccines Market Forecasts, 2011-2021
4.2.1 Forecasts for the Global Vaccines Market, 2010-2015
4.2.2 Forecasts for the Global Vaccines Market, 2016-2021
4.3 Fastest Growing Types of Vaccines, 2011-2021
4.4 Growth in Vaccine Market Will Drive Efficiency in Vaccine Manufacturing
4.5 Global Market for the Manufacture of Vaccines, 2011-2021
4.5.1 Vaccine Manufacturing Market by Volume, 2010
4.5.2 Vaccine Manufacturing Market by Volume, 2010-2021
4.6 Leading National Markets for Vaccine Manufacturing, 2011-2021
4.6.1 Leading Vaccine Manufacturing Destinations, 2010
4.6.2 Leading Vaccine Manufacturing Destinations, 2010-2015
4.6.3 Leading Vaccine Manufacturing Destinations, 2016-2021
4.6.4 Vaccine Production in Developing Countries
4.6.4.1 Promoting Vaccine Production in Developing Countries

5. Outsourcing Vaccine Manufacturing, 2011-2021
5.1 The Challenges in Outsourcing
5.2 Contract Manufacturing Market for Vaccines, 2010-2021
5.2.1 Market Size for Contract Manufacturing of Vaccines, 2010
5.2.2 Forecast for the Vaccine Manufacturing Market, 2010-2015
5.2.3 Forecast for the Vaccine Contract Manufacturing Market, 2016-2021
5.3 Activities Typically Outsourced
5.3.1 Leading Vaccine Contract Manufacturing Organisations
5.3.1.1 SynCo Bio Partners
5.3.1.2 Baxter BioPharma Solutions
5.3.1.3 Meridian Life Sciences
5.4 Changes in the Vaccine Market to Drive Contract Manufacturing
5.5 Trends in Therapeutic Discovery and Manufacturing
5.6 Long-Term Contracts, Strategic Outsourcing and Alliances with Academic Laboratories
5.6.1 Strategic Alliances with Non-Profit and Academic Laboratories

6. Factors Affecting the Vaccine Manufacturing Market
6.1 SWOT Analysis Table
6.2 The Strengths of the Global Vaccine Manufacturing Market
6.2.1 Vaccines are Important Agents for Disease Control
6.2.2 New Vaccine Technologies
6.2.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines
6.2.2.2 New Types of Vaccines
6.2.2.3 New Adjuvants for Vaccines
6.2.2.4 New Vaccine Delivery Mechanisms and Formulations
6.2.2.5 Other Developments in Vaccine Technology
6.2.3 New High-Margin Vaccines
6.2.4 Vaccines Will Not Suffer from Significant Generic Competition
6.2.5 Personalised Vaccines
6.3 The Weaknesses of the Global Vaccine Manufacturing Market
6.3.1 It Remains Difficult to Forecast the Demand for Vaccines
6.3.2 High Costs and Complex Manufacturing Processes
6.3.3 Limitations of the Production Facility: Difficult to Change Over to a Different Product
6.4 Opportunities for Vaccine Manufacturers and Manufacturing Countries
6.4.1 China, India and Brazil Will Become Hubs for Manufacturing Paediatric Vaccines
6.4.2 Vaccines for Diseases Currently Without a Vaccine
6.4.3 Biodefence: Vaccines Against Bioterrorism
6.4.4 Pandemic-Preparedness
6.4.5 Changing World Demographics
6.5 Threats
6.5.1 Consolidation Among Vaccine Manufacturers
6.5.2 Vaccines in the Developing World
6.5.2.1 Vaccine Distribution Networks
6.5.2.2 Vaccine Provision in Developing Countries

7. Research Interviews
7.1 Mr Patrick Lucy, Vice President, Business Development, Pfenex
7.1.1 Pfenex Technology
7.1.2 The Service Offering of Pfenex
7.1.3 The Current State of Vaccine Manufacturing
7.1.4 Novel Platforms Driving the Vaccines Market
7.2 Dr Roger Lias, President & Group Commercial Director, Eden Biodesign
7.2.1 Contract Manufacturing Market
7.2.2 Future Growth Prospects for Vaccines Contract Manufacturing
7.2.3 Capabilities of Eden Biodesign
7.2.4 Industry Drivers

8. Conclusions
8.1 Vaccine Manufacturing Market Will Grow
8.2 Drivers for Change in Vaccines Manufacturing
8.2.1 Market Forces
8.2.2 Technological Developments
8.2.3 Social Forces
8.2.4 Economic Forces
8.3 Trend Towards Greater Use of Disposable Single-Use Systems
8.4 Developing Countries Will Need the Most Vaccines Developed
8.4.1 Africa and Asia Will See Demand for Vaccines Rise
8.4.2 Drug and Vaccine Safety Still a Concern in Developing Countries
8.5 The Balance of Power within the Vaccines Market Will Shift
8.6 Public Misunderstanding of the Dangers of Vaccination Will Continue to Threaten Market Growth
8.7 Generic Vaccines are Unlikely to Threaten Sales of Multi-National Vaccine Manufacturers
8.7.1 Novel Vaccine Technologies Will Drive Growth in this Market

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

For an exec. summary please email Sara Peerun
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)207-336-6100

.